ArticleThe British journal of dermatology2017
Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
Abstract readLetterMulticenter Study
In one paragraph
Article in The British journal of dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Linking ambient air pollution to mental health: evidence based on the two-sample Mendelian randomization and colocalization study.Translational psychiatry · 2024Article
- Association of functional, inherited vitamin D-binding protein variants with melanoma-specific death.JNCI cancer spectrum · 2023Article
- Explainable multi-task learning improves the parallel estimation of polygenic risk scores for many diseases through shared genetic basis.PLoS computational biology · 2023Article
- The Complex Interplay between Nevi and Melanoma: Risk Factors and Precursors.International journal of molecular sciences · 2023Review
- Article
- Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study.Current oncology (Toronto, Ont.) · 2021Article
- Germline variants are associated with increased primary melanoma tumor thickness at diagnosis.Human molecular genetics · 2021Article
- On Naevi and Melanomas: Two Sides of the Same Coin?Frontiers in medicine · 2021Article
- Association of IRF4 single-nucleotide polymorphism rs12203592 with melanoma-specific survival.The British journal of dermatology · 2020Article
- Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.The Journal of investigative dermatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
D C GibbsDepartment of Epidemiology, Emory University, Atlanta, GA, U.S.A.ORCID 0000-0001-7813-6272
S V WardCentre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Western Australia, Australia.
I OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, U.S.A.
G CadbyCentre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Western Australia, Australia.
P A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
L LuoDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM, U.S.A.
K J BusamDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, U.S.A.
A KrickerSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
B K ArmstrongSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
A E CustSydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
H Anton-CulverDepartment of Epidemiology, University of California, Irvine, CA, U.S.A.
R P GallagherCancer Control Research, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
R ZanettiPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
S RossoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
L SacchettoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
D W OllilaDepartment of Surgery, University of North Carolina, Chapel Hill, NC, U.S.A.
C B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, U.S.A.
M BerwickDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, NM, U.S.A.
N E ThomasLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, U.S.A.
GEM Study Group
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVirology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3MMEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3MMelanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4MA MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMAU01CA083180 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 1999 to 2003
$5.2MSolar Exposure and Melanoma SurvivalR01CA112524 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 2005 to 2009
$2.5MEpidemiologic Parameters of Rare Cancer Risk FactorsR01CA098438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BEGG, COLIN B · 2003 to 2005
$839kNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA098438NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA112524NCI NIH HHS U01 CA083180NIEHS NIH HHS P30 ES010126NIGMS NIH HHS T32 GM008169
Abstract
PubMed holds no abstract for this paper.
Indexed as
FemaleGenotypeHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsMaleMelanomaMiddle AgedPolymorphism, Single NucleotidePrognosisSkin NeoplasmsInterferon Regulatory Factor-4Interferon Regulatory Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.